Emergency contraception review: Evidence-based recommendations for clinicians

Clinical Obstetrics and Gynecology

Volumn 57, Issue 4, 2014, Pages 741-750

  Cleland, Kelly ^a   Raymond, Elizabeth G ^b   Westley, Elizabeth ^c   Trussell, James ^a  

^a PRINCETON UNIVERSITY   (United States)

^b GYNUITY HEALTH PROJECTS   (United States)

^c Family Care International   (United States)

Author keywords

Copper IUD; Emergency contraception; Levonorgestrel; Morning after pill; Ulipristal acetate

Indexed keywords

ANTICONVULSIVE AGENT; GRISEOFULVIN; LEVONORGESTREL; POSTCOITUS CONTRACEPTIVE AGENT; RIFAMPICIN; ULIPRISTAL; PREGNANE DERIVATIVE;

BLEEDING; BODY WEIGHT; COPPER INTRAUTERINE DEVICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CONTRACEPTION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERICUM PERFORATUM; NAUSEA; REVIEW; UNITED STATES; VOMITING; PRACTICE GUIDELINE; PROCEDURES;

CONTRACEPTION, POSTCOITAL; CONTRACEPTIVES, POSTCOITAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; NORPREGNADIENES; PRACTICE GUIDELINES AS TOPIC;

EID: 84927586586     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000056     Document Type: Review

References (60)

1. Massai MR, Forcelledo ML, Brache V, et al. Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study Hum Reprod. 2007; 22:434-439.
2. Jesam C, Salvatierra AM, Schwartz J.L., et al. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod. 2010; 25: 368-373.
3. Cleland K, Zhu H, Goldstuck N., et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Human Reprod. 2012; 27:1994-2000.
4. Creinin MD, Schlaff W, Archer D.F., et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2006; 108:1089-1097.
5. Fine P, Mathe H, Ginde S., et al. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010; 115: 257-263.
6. Glasier AF, Cameron S, Fine P., et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010; 375:555-562.
7. von Hertzen H, Piaggio G, Ding J., et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002; 360:1803-1810.
8. Arowojolu AO, Okewole IA, Adekunle AO. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception. 2002; 66:269-273.
9. Ngai SW, Fan S, Li S.Q., et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Hum Reprod. 2005; 20:307-311.
10. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel Contraception. 2011; 84:363-367.
11. Hamoda H, Ashok PW, Flett GMM, et al. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Human Reprod (Oxf). 2005; 20: 2348-2354.
12. Wu S, Wang C, Wang Y., et al. A randomized, double-blind, multicenter study on comparing levonorgestrel and mifepristone for emergency contraception. J Reprod Med. 1999; 8:43-46.
13. Ho PC, Kwan MSW. A prospective randomized comparison of levonorgestrel with the yuzpe regimen in post-coital contraception. Hum Reprod. 1993; 8:389-392.
14. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet. 1998; 352:428-433.
15. Dada OA, Godfrey EM, Piaggio G, et al. A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception. 2010; 82:373-378.
16. Farajkhoda T, Khoshbin A, Enjezab B., et al. Assessment of two emergency contraceptive regimens in Iran: levonorgestrel versus the Yuzpe. Niger J Clin Pract. 2009; 12:450-452.
17. Noe G, Croxatto HB, Maria Salvatierra A, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception. 2011; 84:486-492.
18. Novikova N, Weisberg E, Stanczyk F.Z., et al. Effectiveness of levonorgestrel emergency contraception given before or after ovulation-a pilot study. Contraception. 2007; 75:112-118.
19. Ellertson C, Webb A, Blanchard K., et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstet Gynecol. 2003; 101:1160-1167.
20. Raymond E, Taylor D, Trussell J., et al. Minimum effectiveness of the levonorgestrel regimen of emergency contraception. Contraception. 2004; 69:79-81.
21. Raymond E, Trussell J, Polis CB. Population effect of increased access to emergency contraceptive pills: a systematic review. Obstet Gynecol. 2007; 109:181-188.
22. Polis CB, Schaffer K, Blanchard K., et al. Advance provision of emergency contraception for pregnancy prevention (full review). Cochrane Db Syst Rev. 2010; 3.
23. Raine TR, Harper C, Rocca C.H., et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA. 2005; 293:54-62.
24. Raymond E, Stewart F, Weaver M., et al. Impact of increased access to emergency contraceptive pills: a randomized controlled trial. Obstet Gynecol. 2006; 108:1098-1106.
25. Raymond EG, Weaver MA. Effect of an emergency contraceptive pill intervention on pregnancy risk behavior. Contraception. 2008; 77: 333-336.
26. Turok DK, Jacobson JC, Dermish A.I., et al. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates. Contraception. 2014; 89: 222-228.
27. Faculty of Sexual & Reproductive Healthcare, Clinical Effectiveness Unit. Drug interactions with hormonal contraception. Clin Guidance. 2012.
28. Faculty of Sexual & Reproductive Healthcare, Clinical Effectiveness Unit. Clinical guidance on emergency contraception. Clin Guidance. 2011.
29. Lundsberg LS, Pal L, Gariepy A.M., et al. Knowledge, attitudes, and practices regarding conception and fertility: a population-based survey among reproductive-age United States women. Fertil Steril. 2014; 101:767-774.
30. Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception. 2011; 84:35-39.
31. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 112, Emergency Contraception. Obstet Gynecol. 2010; 115:1100-1108.
32. World Health Organization. Medical eligibility criteria for contraceptive use. 2010; 4th edition. Available at: http://whqlibdoc.who.int/publications/2010/9789241563888-eng.pdf?ua=1.
33. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR. 2010; 59:1-85.
34. Turok DK, Godfrey EM, Wojdyla D, et al. Copper T380 intrauterine device for emergency contraception: Highly effective at any time in the menstrual cycle. Hum Reprod. 2013; 28: 2672-2676.
35. Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception. 2005; 71:395-398.
36. Rickert VI, Tiezzi L, Lipshutz J., et al. Depo now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health. 2007; 40:22-28.
37. Sneed R, Westhoff C, Morroni C., et al. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception. 2005; 71:99-103.
38. Michie L, Cameron S, Glasier A., et al. Pharmacy-based interventions for initiating effective contraception following the use of emergency contraception: a pilot study. Contraception. 2014; 90:447-453.
39. Raymond EG, Halpern V, Lopez LM. Pericoital oral contraception with levonorgestrel: a systematic review. Obstet Gynecol. 2011; 117:673-681.
40. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012; 366: 409-420.
41. National Institutes of Health. Efficacy study of two continuous regimens of oral daily 5mg or 10mg of ulipristal acetate (UPA), versus a dose of 5.0 mg UPA for 24/4 days (CCN013). Available at: http://clinicaltrials.gov/ct2/show/NCT01953679?term=Ulipristal&rank=6. Accessed June 24, 2014.
42. Gemzell-Danielsson K, Berger C, Lalitkumar PGL. Emergency contraception-mechanisms of action. Contraception. 2013; 87:300-308.
43. De Santis M, Cavaliere AF, Straface G, et al. Failure of the emergency contraceptive levonor-gestrel and the risk of adverse effects in pregnancy and on fetal development: an observational cohort study. Fertil Steril. 2005; 84:296-299.
44. Zhang L, Chen J, Wang Y., et al. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod. 2009; 1:1-7.
45. Brache V, Cochon L, Jesam C., et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. 2010; 25:2256-2263.
46. Levy DP, Jager M, Kapp N., et al. Ulipristal acetate for emergency contraception: Postmarketing experience after use by more than 1 million women. Contraception. 2014; 89:431-433.
47. Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists. Use of ulipristal acetate (ellaOne(R)) in breastfeeding women, update from the Clinical Effectiveness Unit. Clin Guidance. 2013.
48. Cleland K, Raymond E, Trussell J., et al. Ectopic pregnancy and emergency contraceptive pills: a systematic review. Obstet Gynecol. 2010; 115:1263-1266.
49. Sufrin CB, Postlethwaite D, Armstrong M.A., et al. Neisseria gonorrhea and chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012; 120:1314-1321.
50. Bergin A, Tristan S, Terplan M., et al. A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception. 2012; 86:694-697.
51. Raymond EG, Goldberg A, Trussell J., et al. Bleeding patterns after use of levonorgestrel emergency contraceptive pills. Contraception. 2006; 73: 376-381.
52. Gainer E, Kenfack B, Mboudou E., et al. Menstrual bleeding patterns following levonorgestrel emergency contraception. Contraception. 2006; 74:118-124.
53. Tirelli A, Cagnacci A, Volpe A. Levonorgestrel administration in emergency contraception: bleeding pattern and pituitary-ovarian function. Contraception. 2008; 77:328-332.
54. Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception. 2009; 79:356-362.
55. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update. 2011; 17:121-137.
56. Task Force on Post-Ovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet. 1998; 352:428-433.
57. Department of Health and Human Services. Letter to NDA/ANDA applicants. Available at: http://www.hpm.com/pdf/blog/PLAN%20B%20-%20FDA%20Exclusivity%20&%20Carve-Out%20 Determination.pdf. Accessed March 3, 2014.
58. American Society for Emergency Contraception. The cost of emergency contraception: Results from a nationwide survey. Available at: http://americansocietyforec.org/uploads/3/2/7/0/3270267/asecpricing report.pdf. Accessed June 24, 2014.
59. Harper CC, Speidel JJ, Drey E.A., et al. Copper intrauterine device for emergency contraception: clinical practice among contraceptive providers. Obstet Gynecol. 2012; 119:220-226.
60. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, Long-Acting Reversible Contraception Working Group. ACOG committee opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol. 2009; 114:1434-1438.